XML 61 R42.htm IDEA: XBRL DOCUMENT
v3.21.1

BUSINESS COMBINATIONS - Definite-Lived Intangible Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Aug. 06, 2020 | Jan. 03, 2020
--- | --- | --- | ---
Distributed Bio, Inc. |  |  |
Business Acquisition [Line Items] |  |  |
Definite-lived intangible assets acquired | $ 24,540 |  |
Weighted-average amortization life | 7 years |  |
Cellero, LLC |  |  |
Business Acquisition [Line Items] |  |  |
Definite-lived intangible assets acquired |  | $ 16,230 |
Weighted-average amortization life |  | 12 years |
HemaCare Corporation |  |  |
Business Acquisition [Line Items] |  |  |
Definite-lived intangible assets acquired |  |  | $ 183,540
Weighted-average amortization life |  |  | 18 years
Customer and client relationships | Distributed Bio, Inc. |  |  |
Business Acquisition [Line Items] |  |  |
Definite-lived intangible assets acquired | $ 16,080 |  |
Weighted-average amortization life | 9 years |  |
Customer and client relationships | Cellero, LLC |  |  |
Business Acquisition [Line Items] |  |  |
Definite-lived intangible assets acquired |  | $ 14,740 |
Weighted-average amortization life |  | 13 years |
Customer and client relationships | HemaCare Corporation |  |  |
Business Acquisition [Line Items] |  |  |
Definite-lived intangible assets acquired |  |  | $ 170,390
Weighted-average amortization life |  |  | 19 years
Developed technology | Distributed Bio, Inc. |  |  |
Business Acquisition [Line Items] |  |  |
Definite-lived intangible assets acquired | $ 3,940 |  |
Weighted-average amortization life | 5 years |  |
Trade name | HemaCare Corporation |  |  |
Business Acquisition [Line Items] |  |  |
Definite-lived intangible assets acquired |  |  | $ 7,330
Weighted-average amortization life |  |  | 10 years
Other intangible assets | Distributed Bio, Inc. |  |  |
Business Acquisition [Line Items] |  |  |
Definite-lived intangible assets acquired | $ 4,520 |  |
Weighted-average amortization life | 4 years |  |
Other intangible assets | Cellero, LLC |  |  |
Business Acquisition [Line Items] |  |  |
Definite-lived intangible assets acquired |  | $ 1,490 |
Weighted-average amortization life |  | 3 years |
Other intangible assets | HemaCare Corporation |  |  |
Business Acquisition [Line Items] |  |  |
Definite-lived intangible assets acquired |  |  | $ 5,820
Weighted-average amortization life |  |  | 3 years

X
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=crl_DistributedBioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=crl_CelleroLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=crl_HemaCareCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |